254 related articles for article (PubMed ID: 29651291)
1. Cutting an NKG2D Ligand Short: Cellular Processing of the Peculiar Human NKG2D Ligand ULBP4.
Zöller T; Wittenbrink M; Hoffmeister M; Steinle A
Front Immunol; 2018; 9():620. PubMed ID: 29651291
[TBL] [Abstract][Full Text] [Related]
2. Stress Signal ULBP4, an NKG2D Ligand, Is Upregulated in Multiple Sclerosis and Shapes CD8
Carmena Moratalla A; Carpentier Solorio Y; Lemaitre F; Farzam-Kia N; Levert A; Zandee SEJ; Lahav B; Guimond JV; Haddad E; Girard M; Duquette P; Larochelle C; Prat A; Arbour N
Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34873031
[TBL] [Abstract][Full Text] [Related]
3. MICAgen Mice Recapitulate the Highly Restricted but Activation-Inducible Expression of the Paradigmatic Human NKG2D Ligand MICA.
Kim Y; Born C; Bléry M; Steinle A
Front Immunol; 2020; 11():960. PubMed ID: 32582150
[TBL] [Abstract][Full Text] [Related]
4. The NKG2D ligand ULBP4 is not expressed by human monocytes.
Lazarova M; Kim Y; Steinle A
PLoS One; 2021; 16(2):e0246726. PubMed ID: 33556116
[TBL] [Abstract][Full Text] [Related]
5. Four novel ULBP splice variants are ligands for human NKG2D.
Cao W; Xi X; Wang Z; Dong L; Hao Z; Cui L; Ma C; He W
Int Immunol; 2008 Aug; 20(8):981-91. PubMed ID: 18544572
[TBL] [Abstract][Full Text] [Related]
6. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
7. The NKG2D ligand ULBP4 binds to TCRgamma9/delta2 and induces cytotoxicity to tumor cells through both TCRgammadelta and NKG2D.
Kong Y; Cao W; Xi X; Ma C; Cui L; He W
Blood; 2009 Jul; 114(2):310-7. PubMed ID: 19436053
[TBL] [Abstract][Full Text] [Related]
8. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
9. Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the alpha2 domain.
Wittenbrink M; Spreu J; Steinle A
Eur J Immunol; 2009 Jun; 39(6):1642-51. PubMed ID: 19424970
[TBL] [Abstract][Full Text] [Related]
10. ULBP4 is a novel ligand for human NKG2D.
Chalupny NJ; Sutherland CL; Lawrence WA; Rein-Weston A; Cosman D
Biochem Biophys Res Commun; 2003 May; 305(1):129-35. PubMed ID: 12732206
[TBL] [Abstract][Full Text] [Related]
11. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
12. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
Raffaghello L; Prigione I; Airoldi I; Camoriano M; Levreri I; Gambini C; Pende D; Steinle A; Ferrone S; Pistoia V
Neoplasia; 2004; 6(5):558-68. PubMed ID: 15548365
[TBL] [Abstract][Full Text] [Related]
13. Decreased expression of the NKG2D ligand ULBP4 may be an indicator of poor prognosis in patients with nasopharyngeal carcinoma.
Xu Y; Zhou L; Zong J; Ye Y; Chen G; Chen Y; Liao X; Guo Q; Qiu S; Lin S; Chen H; Pan J
Oncotarget; 2017 Jun; 8(26):42007-42019. PubMed ID: 28159927
[TBL] [Abstract][Full Text] [Related]
14. NKG2D ligand expression in Crohn's disease and NKG2D-dependent stimulation of CD8
Vadstrup K; Galsgaard ED; Jensen H; Lanier LL; Ryan JC; Chen SY; Nolan GP; Vester-Andersen MK; Pedersen JS; Gerwien J; Jensen T; Bendtsen F
Exp Mol Pathol; 2017 Aug; 103(1):56-70. PubMed ID: 28684217
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical validation and expression profiling of NKG2D ligands in a wide spectrum of human epithelial neoplasms.
Fujita H; Hatanaka Y; Sutoh Y; Suzuki Y; Oba K; Hatanaka KC; Mitsuhashi T; Otsuka N; Fugo K; Kasahara M; Matsuno Y
J Histochem Cytochem; 2015 Mar; 63(3):217-27. PubMed ID: 25473094
[TBL] [Abstract][Full Text] [Related]
16. Characterization of 5' promoter and exon 1-3 polymorphism of the RAET1E gene.
Cox ST; Pearson H; Laza-Briviesca R; Pesoa S; Vullo C; Madrigal JA; Saudemont A
Hum Immunol; 2016 Jan; 77(1):96-103. PubMed ID: 26519211
[TBL] [Abstract][Full Text] [Related]
17. Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
Waldhauer I; Steinle A
Cancer Res; 2006 Mar; 66(5):2520-6. PubMed ID: 16510567
[TBL] [Abstract][Full Text] [Related]
18. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein.
Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C
J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260
[TBL] [Abstract][Full Text] [Related]
19. Upregulated expression of NKG2D and its ligands give potential therapeutic targets for patients with thymoma.
Xuan XY; Zhang JF; Hu GM; Li QR; Liu PP; Du Y
Cancer Gene Ther; 2015 Jul; 22(7):368-74. PubMed ID: 26113176
[TBL] [Abstract][Full Text] [Related]
20. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H; Kim J; Cosman D; Choi I
Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
